Robust growth fuels Eton Pharmaceuticals, but the biotech faces key test.
Eton Pharmaceuticals (NasdaqGM:ETON) announced a new ET-900 development program for infantile and epileptic spasms on 9 November 2026. Management said ET-900 is supported by preclinical evidence and external partnerships focused on epilepsy treatment research. The company released preliminary clinical results for its ET-700 formulation in Wilson disease, highlighting early patient data from an ongoing study. The ET-900 launch and first ET-700 readout only tell part of Eton's wider R&D story...
Eton Pharmaceuticals reported third quarter 2026 revenue of US$57.93 million and net income of US$35.25 million, reversing a loss from a year earlier and delivering US$1.06 in diluted earnings per share from continuing operations. The business lifted full year 2026 revenue guidance from more than US$145 million to more than US$175 million, indicating management confidence in demand for its branded rare disease portfolio and expanding pipeline. We will now see how Eton Pharmaceuticals’ sharp...
Eton Pharmaceuticals (ETON) stock surged after strong Q3 earnings, 158% revenue growth, and a raised outlook. Read more here.
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2026 financial results on Thursday, November 5, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET. Participant Call Link: Click HereWebcast:Click Here In addition to
RARE, BHVN, DYN, UNCY, KURA, QURE, PHVS, SVRA, MESO, GRCE_______________________________________________Initiating coverage at BUY | 12-month price target...
Detailed price information for Si-Bone Inc (SIBN-Q) from The Globe and Mail including charting and trades.
Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.
Detailed price information for Eton Pharmaceutcials Inc (ETON-Q) from The Globe and Mail including charting and trades.
During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to “cut it off” or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is now above $60. In response, Jim Cramer said: I think you take […]
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your
David Krempa, Chief Business Officer, on August 24, 2026, sold 25,000 shares in Eton Pharmaceuticals
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.
This is the newest page. Registered accounts read further back.